GlassScriptPhysician profile
Sampada Acharya
NPI 1033422662
$3,106.51
in general payments reported to CMS, 2019-2025
38 companies · $658 in 2025
The $658 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.34 · 2021: $334 · 2022: $360 · 2023: $496 · 2024: $1,174 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,308 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.37 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $973.40 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $404.54 | 2022-2025 | Tavneos, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $183.68 | 2021-2025 | Benlysta |
| Ucb, INC. | $169.85 | 2021-2025 | Bimzelx, Cimzia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.33 | 2021-2025 | Xifaxan |
| Pfizer INC. | $101.31 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $91.15 | 2024 | Lupkynis |
| Insulet Corporation | $84.29 | 2024-2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $80.03 | 2022-2024 | Gattex, Eohilia |
| Novartis Pharmaceuticals Corporation | $68.29 | 2024-2025 | |
| Neuraxis, INC. | $67.55 | 2025 | |
| Phathom Pharmaceuticals, INC. | $60.77 | 2024-2025 | Voquezna |
| Horizon Therapeutics Plc | $57.81 | 2021-2023 | Krystexxa |
| Janssen Biotech, INC. | $50.27 | 2023-2024 | Stelara, Simponi Aria, Tremfya |
| Lilly USA, LLC | $49.85 | 2021-2023 | Taltz |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $46.76 | 2023-2024 | Hyrimoz |
| Abbott Laboratories | $44.56 | 2024 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.52 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $33.46 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $32.79 | 2021-2024 | Zinplava, Dificid |
| Actelion Pharmaceuticals US, INC. | $31.29 | 2023 | Uptravi, Opsumit |
| Beta Bionics, INC. | $28.86 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alcresta Therapeutics, INC. | $28.75 | 2024 | Relizorb |
| Ethicon US, LLC | $28.21 | 2024 | Vistaseal |
| Hologic INC | $26.51 | 2022 | |
| Qol Medical, LLC | $25.46 | 2022 | |
| Genentech USA, INC. | $19.79 | 2021 | |
| Boston Scientific Corporation | $19.43 | 2024 | Varithena Administration Pack |
| Enterra Medical, INC. | $19.22 | 2024 | |
| Aimmune Therapeutics, INC. | $16.96 | 2025 | Zenpep |
| Xeris Pharmaceuticals, INC. | $16.68 | 2025 | Recorlev |
| Medtronic, INC. | $16.15 | 2023 | Minimed 780g |
| Braintree Laboratories, INC. | $14.45 | 2022 | |
| Tactile Systems Technology INC | $14.24 | 2023 | Flexitouch Plus, Entre Plus |
| Nestle Healthcare Nutrition INC. | $13.92 | 2021 | |
| Alfasigma USA, INC. | $13.27 | 2021 | |
| Myriad Genetic Laboratories, INC. | $13.16 | 2023 | Myrisk |
| Thd America, INC. | $11.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sampada Acharya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.